Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Regeneron (REGN) stock drops 18% as trial data for COPD therapy developed with Sanofi (SNY) leads to a downgrade at Wells Fargo. Read more here.

Is Regeneron stock a buy now? Per the terms of the agreement, Regeneron will pay an upfront amount of $80 million, with potential clinical and regulatory milestones of up to $1.93 billion, in ...

Value. 67.49. Price Trend. Short. ... If an investor had bought $100 of REGN stock 20 years ago, it would be worth $6,185.92 today based on a price of $509.72 for REGN at the time of writing.

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy itepekimab in former smokers. Read more here.

Shares of Regeneron Pharmaceuticals Inc. REGN shed 1.24% to $522.68 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.94 ...

Shares of Regeneron (REGN-1.44%) have declined this year due to issues with one of its former growth drivers, Eylea, a medicine that treats wet age-related macular degeneration. The therapy is ...